Biopharmaceutical company Insmed appoints new general counsel

Christine Pellizzari has joined Insmed, a biopharmaceutical company focused on lung disease treatments headquartered in New Jersey, as general counsel and corporate secretary. She took up the role at the end of July.

Pellizzari joins with almost 20 years experience of senior level leadership in the global biotechnology and pharmaceutical industry. Prior to her appointment she was executive vice president, general counsel and corporate secretary at Aegerion Pharmaceuticals from 2007 to 2012, and before that had been senior vice president, general counsel and corporate secretary at Dendrite from 1998. She has also worked as an associate in the corporate and healthcare departments of Wilentz Goldman & Spitzer.

Will Lewis, president and chief executive officer of Insmed said of the move: "I am particularly pleased to welcome Christine to the Insmed team. Having worked with Christine while at Aegerion, I know first-hand that she will be an invaluable asset to the company. Christine has broad legal experience with both development and commercial stage pharmaceutical companies. Her significant leadership experience will provide new insight and valuable perspective as we look to transition the company to a commercial entity and build Insmed into a leading biopharmaceutical company.”

Of the move Pellizzari said: "It is a pleasure to be joining the Insmed team at this important juncture in the company's development. The company's focus on developing new therapeutics for unmet medical needs at the intersection of pulmonary, infectious and orphan diseases offers a very exciting opportunity. I look forward to being a part of this dynamic leadership team as we bring new treatments to patients suffering from these serious lung diseases."

Insmed is a biopharmaceutical company which develops and commercialises inhaled anti-infective medications to treat patients battling serious lung diseases such as cystic fibrosis and patients with non-tuberculous mycobacteria lung infections.

Back to top

Follow us on LinkedIn

News & Features

Community News

Analysis

Features

Pro Bono

Corporate Counsel

Women in Law

Future Leaders

Research Reports

Practice Areas

Firms

The Who's Who Legal 100

Awards

Special Reports

Events

Shop

About Us

Research Schedule

It is not possible to buy entry into any Who's Who Legal publication

Nominees have been selected based upon comprehensive, independent survey work with both general counsel and private practice lawyers worldwide. Only specialists who have met independent international research criteria are listed.

Copyright © 2018 Law Business Research Ltd. All rights reserved. | http://www.lbresearch.com

87 Lancaster Road, London, W11 1QQ, UK | Tel: +44 20 7908 1180 / Fax: +44 207 229 6910

http://www.whoswholegal.com | editorial@whoswholegal.com

Law Business Research Ltd

87 Lancaster Road, London
W11 1QQ, UK